Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients

被引：28

作者：

Dvojkovic, Anja ^{[1
]}

Perkovic, Matea Nikolac ^{[2
]}

Sagud, Marina ^{[3
,4
]}

Erjavec, Gordana Nedic ^{[2
]}

Peles, Alma Mihaljevic ^{[3
,4
]}

Strac, Dubravka Svob ^{[2
]}

Cusa, Bjanka Vuksan ^{[3
,4
]}

Tudor, Lucija ^{[2
]}

Kusevic, Zorana ^{[3
,4
]}

Konjevod, Marcela ^{[2
]}

Zivkovic, Maja ^{[4
]}

Jevtovic, Sasa ^{[3
,4
]}

Pivac, Nela ^{[2
]}

机构：

[1] Univ Psychiat Hosp Vrapce, Bolnicka Cesta 32, HR-10090 Zagreb, Croatia

[2] Rudjer Boskovic Inst, Bijenicka Cesta 54, HR-10000 Zagreb, Croatia

[3] Univ Zagreb, Sch Med, Salata 3, HR-10000 Zagreb, Croatia

[4] Univ Hosp Ctr Zagreb, Dept Psychiat & Psychol Med, Zagreb, Croatia

来源：

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 2021年 / 105卷

关键词：

Depression; Escitalopram; Plasma BDNF; Platelet serotonin; Patients; Vortioxetine; PERIPHERAL BIOCHEMICAL MARKERS; NEUROTROPHIC FACTOR LEVELS; MAJOR DEPRESSION; ANTIDEPRESSANT VORTIOXETINE; BLOOD-BRAIN; SHORT-TERM; SERUM; PAROXETINE; DISORDER; BIOMARKER;

D O I：

10.1016/j.pnpbp.2020.110016

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Escitalopram and vortioxetine are efficacious antidepressants. They directly target serotonin (5-HT) system, but vortioxetine mechanism of action is distinct from the one of selective serotonin reuptake inhibitors (SSRIs). Treatment with SSRIs decrease platelet 5-HT concentration and increase peripheral brain-derived neurotrophic factor (BDNF) levels. Since vortioxetine has a multimodal mechanism of action, it is expected to have a greater effect on circulatory BDNF concentration, compared to conventional antidepressants. This longitudinal study aimed to explore and compare the effects of 4-weeks of treatment with vortioxetine and escitalopram on plasma BDNF and platelet 5-HT concentration in patients with major depressive disorder (MDD). The results revealed that vortioxetine significantly increased plasma BDNF concentration (p = .018) and significantly decreased platelet 5-HT concentration (p < .001). Treatment with escitalopram significantly decreased platelet 5-HT concentration (p < .001), but it did not affect plasma BDNF concentration (p = .379). Response to vortioxetine was not predicted by baseline plasma BDNF or platelet 5-HT concentration, but response to escitalopram was predicted by baseline platelet 5-HT concentration. These effects might be due to vortioxetine unique mechanism of action, but the clinical implications are unclear. It remains to be determined whether this finding extends during long-term vortioxetine treatment, and which, if any, clinical effects emerge from BDNF increase.

引用

页数：11

共 50 条

[21] Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity [J].

Karege, F ;

Bondolfi, G ;

Gervasoni, N ;

Schwald, M ;

Aubry, JM ;

Bertschy, G .

BIOLOGICAL PSYCHIATRY, 2005, 57 (09) :1068-1072

[22] BDNF plasma levels variations in major depressed patients receiving duloxetine [J].

Michele Fornaro ;

Andrea Escelsior ;

Giulio Rocchi ;

Benedetta Conio ;

Paola Magioncalda ;

Valentina Marozzi ;

Andrea Presta ;

Bruno Sterlini ;

Paola Contini ;

Mario Amore ;

Pantaleo Fornaro ;

Matteo Martino .

Neurological Sciences, 2015, 36 :729-734

[23] BDNF plasma levels variations in major depressed patients receiving duloxetine [J].

Fornaro, Michele ;

Escelsior, Andrea ;

Rocchi, Giulio ;

Conio, Benedetta ;

Magioncalda, Paola ;

Marozzi, Valentina ;

Presta, Andrea ;

Sterlini, Bruno ;

Contini, Paola ;

Amore, Mario ;

Fornaro, Pantaleo ;

Martino, Matteo .

NEUROLOGICAL SCIENCES, 2015, 36 (05) :729-734

[24] Alteration of Decreased Plasma NO Metabolites and Platelet NO Synthase Activity by Paroxetine in Depressed Patients [J].

Wendy Chrapko ;

Paul Jurasz ;

Marek W Radomski ;

Stephen L Archer ;

Stephen C Newman ;

Glen Baker ;

Nathalie Lara ;

Jean-Michel Le Mellédo .

Neuropsychopharmacology, 2006, 31 :1286-1293

[25] Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients [J].

Chrapko, Wendy ;

Jurasz, Paul ;

Radomski, Marek W. ;

Archer, Stephen L. ;

Newman, Stephen C. ;

Baker, Glen ;

Lara, Nathalie ;

Le Mellédo, Jean-Michel .

NEUROPSYCHOPHARMACOLOGY, 2006, 31 (06) :1286-1293

[26] SEROTONIN-INDUCED PLATELET INTRACELLULAR CALCIUM MOBILIZATION IN DEPRESSED-PATIENTS [J].

KUSUMI, I ;

KOYAMA, T ;

YAMASHITA, I .

PSYCHOPHARMACOLOGY, 1994, 113 (3-4) :322-327

[27] Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine [J].

Javors, MA ;

Houston, JP ;

Tekell, JL ;

Brannan, SK ;

Frazer, A .

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2000, 3 (03) :229-235

[28] The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients [J].

Yoshimura, Reiji ;

Kishi, Taro ;

Suzuki, Akihito ;

Umene-Nakano, Wakako ;

Ikenouchi-Sugita, Atsuko ;

Hori, Hikaru ;

Otani, Koichi ;

Iwata, Nakao ;

Nakamura, Jun .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (04) :1022-1025

[29] Altered serotonin and dopamine transporter availabilities in brain of depressed patients upon treatment with escitalopram: A [123I]β-CIT SPECT study [J].

Rominger, A. ;

Cumming, P. ;

Brendel, M. ;

Xiong, G. ;

Zach, C. ;

Karch, S. ;

Tatsch, K. ;

Bartenstein, P. ;

la Fougere, C. ;

Koch, W. ;

Pogarell, O. .

EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (06) :873-881

[30] Plasma Serotonin and Kynurenine Pathway Metabolite Levels in Depression Patients Treated With Escitalopram and Desvenlafaxine [J].

Sun, Yu ;

Drevets, Wayne ;

Turecki, Gustavo ;

Li, Qingqin .

NEUROPSYCHOPHARMACOLOGY, 2017, 42 :S164-S165

← 1 2 3 4 5 →